Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers

NCT07530185 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-07-08

Condition(s) studied

Sports Performance

Investigational drug(s) / intervention(s)

PlaceboL-TyrosineCaffeineL-tyrosine + Caffeine

Placebo: Placebo solution matched in taste and volume to active supplements.

L-Tyrosine: L-tyrosine at 150 mg/kg body weight administered 60 minutes before exercise.

Caffeine: Caffeine at 5 mg/kg body weight administered 60 minutes before exercise.

L-tyrosine + Caffeine: Combined L-tyrosine (150 mg/kg) and caffeine (5 mg/kg) administered 60 minutes before exercise.

Study summary

Participants will complete six sessions, including one familiarization and baseline session followed by five experimental conditions: control (no supplementation), placebo, L-tyrosine, caffeine, and combined L-tyrosine plus caffeine. The experimental conditions will be performed in a randomized, counterbalanced crossover design with a washout period of at least 72 hours between sessions. Resting physiological and cognitive assessments will be performed during the familiarization session, while biochemical, cognitive, and boxing-specific performance assessments will be conducted before and after each experimental session.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Male elite boxers aged ≥18 years At least 8 years of boxing training experience Active participation in national or international competitions Regular training schedule No injury or illness affecting performance Exclusion Criteria: Use of nutritional supplements or stimulants within the last 4 weeks Any cardiovascular, metabolic, or neurological disorder Current injury or musculoskeletal limitation Smoking or excessive caffeine intake Failure to comply with study procedures

Primary outcome measure(s)

  • Stroop Test Performance — up to 12 weeks
    Cognitive performance assessed using the Stroop test, including reaction time and accuracy.

Trial sites (1)

FacilityCityRegionStatus
Ataturk University Faculty of Sport Sciences Erzurum Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07530185 on ClinicalTrials.gov ↗ ← All trials in Turkey